3 May 2021 - - US-based Genesis Therapeutics, a company developing AI technologies to create medicines for patients with severe and unmet medical needs, has appointed Will McCarthy as chief business officer, the company said.

Previously McCarthy was chief business officer at Generation Bio, a gene therapy company, and was part of the team that took the company public in 2020.

Before that he was chief business officer at Ignyta, a company focused on genetically defined cancers, and held that role until the acquisition by Roche in 2018.

Earlier in his career he was vice president of corporate development at Foundation Medicine and held business development and commercial roles at Halozyme Therapeutics, Biogen Idec and Neurocrine Biosciences.

He began his career as a strategy consultant at IMS health and Deloitte Consulting and obtained a Master of Business Administration from London Business School and a Bachelor of Arts degree in economics from the University of Exeter.

McCarthy joins Genesis Therapeutics at the same time as the company was selected for the Forbes AI 50 Companies to Watch list for the second consecutive year.

Genesis Therapeutics completed a USD 52m series A round of financing in December 2020 and is progressing both an internal drug pipeline, as well as select external partnerships, to create transformative therapies for patients.

The company announced a multi-target partnership with US-based biotechnology company Genentech in October 2020. Genentech is part of Switzerland's Roche (SIX: RO) (OTCQX: RHHBY).

Genesis Therapeutics has developed Dynamic PotentialNet and other novel neural network algorithms that examine drug-target complexes as flexible, spatial graphs -- enabling superior prediction of potency and selectivity of drug candidates.

The company's technology offers significant advantages in addressing novel, previously undruggable targets in addition to well-characterized therapeutic targets.

Genesis Therapeutics' AI engineering team partners closely with its medicinal chemists to execute and continuously strengthen an innovative process for drug discovery and early development.

Genesis Therapeutics' robust infrastructure scales the company's AI platform on the Cloud, enabling the company to combine its proprietary Molecular Generation Engine with its field-leading molecular property predictors to search immense swaths of chemical space, approaching drug discovery as a multiparameter optimization problem.

Genesis Therapeutics is a biotechnology company that invents and deploys breakthrough AI techniques to discover and develop drugs both internally as well as in select partnerships.

Genesis Therapeutics is unique in its groundbreaking deep learning technology, its synergy of machine learning with biophysical simulation and its pairing of AI with extensive biotech/pharma expertise.

Genesis Therapeutics was founded in 2019 with origins in AI research at Stanford University by its co-founder and CEO, Evan Feinberg, Ph.D. The company is headquartered in Burlingame, CA.